• Wondering whether Xenon Pharmaceuticals at around US$56 a share still offers value, or if most of the opportunity has already been priced in.
• The stock has slipped 0.1% over the past week and 2.9% over the past month, yet it is still up 25.9% year to date and 57.6% over the last year. This can change how you think about both upside and risk.
• Recent attention on Xenon has centered on how its share price performance compares with other biotech stocks and what that says about investor expectations. Coverage has increasingly focused on whether the current price lines up with the company’s fundamentals and long term prospects.
• Xenon currently holds a 4 out of 6 valuation score. This article will walk through the key valuation approaches behind that figure, then finish with a way of looking at value that can give an even clearer picture.

Approach 1: Xenon Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows, then discounts them back to what they might be worth in today’s dollars. It is essentially asking what a stream of future cash flows could reasonably be worth right now.

For Xenon Pharmaceuticals, the latest twelve month Free Cash Flow (FCF) is a loss of $288.609 million. Analysts provide FCF estimates out to 2030, with Simply Wall St extending the path using a 2 Stage Free Cash Flow to Equity model. Within that, projected annual FCF moves from losses, such as $397.250 million in 2026 and $330.800 million in 2027, to positive figures like $336 million in 2030, all in US$ terms.

When all these cash flows are discounted back using this approach, the estimated intrinsic value comes out at about $312.27 per share, compared with a current price around $56. On this basis, the model suggests Xenon is 82.1% undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Xenon Pharmaceuticals is undervalued by 82.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Xenon Pharmaceuticals Price vs Book

For companies that are not yet profitable, earnings based metrics like P/E are less useful, so investors often look at asset based measures such as the Price to Book ratio. P/B compares the market value of a company with its net assets, which can be a practical way to think about value when profits are not the main anchor.

What counts as a “normal” P/B ratio often reflects how the market views a company’s growth potential and risk. Higher growth or lower perceived risk can support a higher multiple, while lower growth or higher risk usually point to a lower one.

Xenon currently trades on a P/B of 9.30x. This sits above the Biotechs industry average of 2.46x but below the peer group average of 33.09x. Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/B might be, given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it is tailored to Xenon’s own profile rather than broad group averages, it can give a more targeted view than simple industry or peer comparisons.

As the Fair Ratio figure is not available here, there is not enough information to clearly judge Xenon as overvalued or undervalued on a P/B basis alone.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Xenon Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in. A Narrative is simply your story about a company, linked directly to your numbers, such as what you think is a fair value, and how you see future revenue, earnings and margins playing out. Instead of looking at forecasts in isolation, a Narrative connects Xenon Pharmaceuticals’ story to your financial forecast and then to your fair value, so you can clearly see how your view translates into a price. Narratives on Simply Wall St, available on the Community page used by millions of investors, are designed to be easy to set up and update. They can help you compare your Fair Value to the current market price, and they refresh automatically when new information like news or earnings is added. For example, one investor might think Xenon could be worth far more than today’s price while another might see only limited upside, leading to two very different fair values built on two different stories.

Do you think there's more to the story for Xenon Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.